Trilogy Capital Inc. Purchases 30,679 Shares of Medtronic PLC $MDT

Key Points

• Trilogy Capital Inc. increased its stake in Medtronic by 435% in Q4, buying 30,679 shares to hold 37,731 shares valued at about $3.62 million.
• Medtronic slightly beat the quarter with $1.36 EPS vs. $1.34 expected and $9.02 billion in revenue, set FY2026 guidance of 5.62–5.66 EPS, and announced a quarterly dividend of $0.71 per share (3.2% yield).
• EVP Harry Skip Kiil sold 52,524 shares on Feb. 19 at an average price of $97.71 for roughly $5.13 million, reducing his position by 61.6%; insiders now own 0.26% of the stock.

Trilogy Capital Inc. grew its position in Medtronic PLC (NYSE:MDT - Free Report) by 435.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,731 shares of the medical technology company's stock after acquiring an additional 30,679 shares during the period. Trilogy Capital Inc.'s holdings in Medtronic were worth $3,624,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of MDT. Brighton Jones LLC raised its position in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock worth $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC raised its position in Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company's stock worth $380,000 after purchasing an additional 381 shares during the last quarter. Jump Financial LLC bought a new position in Medtronic in the 2nd quarter worth approximately $299,000. Intact Investment Management Inc. raised its position in Medtronic by 28.8% in the 2nd quarter. Intact Investment Management Inc. now owns 40,200 shares of the medical technology company's stock worth $3,504,000 after purchasing an additional 9,000 shares during the last quarter. Finally, Dearborn Partners LLC raised its position in Medtronic by 2.3% in the 2nd quarter. Dearborn Partners LLC now owns 60,187 shares of the medical technology company's stock worth $5,247,000 after purchasing an additional 1,337 shares during the last quarter. Institutional investors own 82.06% of the company's stock.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.26% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an "overweight" rating and a $114.00 price objective for the company. Evercore dropped their price objective on shares of Medtronic from $115.00 to $108.00 and set an "outperform" rating for the company in a research report on Monday. Sanford C. Bernstein boosted their price objective on shares of Medtronic from $111.00 to $112.00 and gave the stock an "outperform" rating in a research report on Friday, January 9th. Piper Sandler dropped their price objective on shares of Medtronic from $105.00 to $91.00 and set a "neutral" rating for the company in a research report on Wednesday, April 1st. Finally, Leerink Partners restated an "outperform" rating and issued a $119.00 price objective on shares of Medtronic in a research report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, Medtronic currently has a consensus rating of "Moderate Buy" and an average target price of $109.10.

Medtronic Stock Performance

Shares of Medtronic stock opened at $87.93 on Friday. The firm has a fifty day moving average of $93.39 and a two-hundred day moving average of $96.02. The stock has a market capitalization of $112.90 billion, a price-to-earnings ratio of 24.49, a PEG ratio of 2.30 and a beta of 0.75. Medtronic PLC has a 52 week low of $79.93 and a 52 week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT - Get Free Report) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts' expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. Medtronic's payout ratio is presently 79.11%.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance for Stealth AXiS expands Medtronic’s addressable market beyond spine into cranial and ENT robotic-assisted surgery, supporting upside to robotics/OR growth expectations. Assessing Medtronic (MDT) Valuation After Stealth AXiS FDA Clearance
• Positive Sentiment: Recent sessions saw MDT outperform the broader market on positive sentiment and technical momentum, reflecting investor interest after earnings and product news. Medtronic (MDT) Beats Stock Market Upswing
• Positive Sentiment: Sector research points to multi-year growth in anesthesia & respiratory devices — an addressable market where Medtronic is a named leader, supporting medium-term revenue tailwinds. Global Anesthesia and Respiratory Devices Market Size/Share
• Neutral Sentiment: Industry board moves and small-cap clinical awards (Telix, Frontier Bio, Circa) are market noise for MDT—important for sector context but unlikely to materially move Medtronic shares on their own. Telix Strengthens Board Frontier Bio Wins 'Best Paper' CIRCA Board Appointment
• Negative Sentiment: Evercore trimmed its price target to $108, reducing near-term upside expectations and contributing to selling pressure. Evercore Cuts Medtronic Price Target to $108
• Negative Sentiment: Stifel cut its price target to $95, adding downward pressure by lowering analyst support levels investors use for benchmarking. Stifel Cuts Medtronic Price Target to $95
• Negative Sentiment: Citigroup published a pessimistic forecast for MDT, which likely amplified intraday selling and outweighed some of the positive product and sector news. Citigroup Issues Pessimistic Forecast for Medtronic

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.